Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s ...

The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.

Teva Pharmaceutical Industries (TEVA) is back on investor radars after recent share price swings, with the stock closing at ...

Danish drugmaker Novo Nordisk faces a class action lawsuit in New York. The company is accused of using its patents to keep a ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...